Abstract：【Objective】To investigate the efficacy of N-acetylcysteine combined with bilateral positive airway pressure (Bi-PAP) and its influence on immune function in the treatment of elderly chronic obstructive pulmonary disease (COPD) with respiratory failure.【Methods】Eighty elderly patients with COPD and respiratory failure admitted to our hospitals from January 2021 to January 2023 were selected and divided into the control group (receiving Bi-PAP therapy) and the observation group (receiving N-acetylcysteine therapy in addition to the control group) by random number table method. The differences in pulmonary function indicators (FEV1, FVC, FEV1/FVC), arterial blood gas analysis indicators (PaO2, PaCO2), immune function indicators (CD4+, CD8+, CD4+/CD8+), oxidative stress indicators (SOD, MDA), modified British Medical Research Council dyspnea index (mMRC) score, COPD Assessment Test (CAT) score, and incidence of adverse reactions were compared between the two groups.【Results】After treatment, the FVC, FEV1, FEV1/FVC, and PaO2 in the observation group were higher than those in the control group (P<0.05), and the PaCO2 in the observation group was lower than that in the control group (P<0.05). After treatment, the mMRC and CAT scores in the observation group were lower than those in the control group (P<0.05). After treatment, the CD4+ and CD4+/CD8+ in the observation group were higher than those in the control group, and the CD8+ was lower than that in the control group, with statistically significant differences (P<0.05). After treatment, the SOD in the observation group was higher than that in the control group, and the MDA was lower than that in the control group, with statistically significant differences (P<0.05). The total incidence of adverse reactions in the two groups was similar, with no statistically significant difference (P>0.05).【Conclusion】The combination of N-acetylcysteine and Bi-PAP therapy in elderly patients with COPD and respiratory failure can not only effectively improve their pulmonary function, dyspnea symptoms, arterial blood gas analysis indicators, and quality of life, but also improve their immune function and oxidative stress indicators. It has good safety.
李彦斌, 杨梦鸿, 王粉利, 武卫东. N-乙酰半胱氨酸联合Bi-PAP治疗老年COPD合并呼吸衰竭患者的疗效及对患者免疫功能的影响[J]. 医学临床研究, 2024, 41(11): 1707-1710.
LI Yanbin, YANG Menghong, WANG Fenli, et al. Efficacy and Immune Function of N-acetylcysteine Combined with Bi-PAP in Elderly COPD Patients with Respiratory Failure. JOURNAL OF CLINICAL RESEARCH, 2024, 41(11): 1707-1710.
2024, Vol. 41 
